<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (P-gp) expression in mononuclear bone marrow cells was analyzed in 119 patients, including 60 with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 48 with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and 11 with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>For P-gp measurement an immunocytological method using monoclonal antibodies C219, 4E3, and MRK 16 and the reverse transcription-polymerase chain reaction technique were applied </plain></SENT>
<SENT sid="2" pm="."><plain>According to our results obtained in healthy volunteers using the immunocytological method, the limit for P-gp overexpression was set at &gt; or = 10% P-gp-positive mononuclear bone marrow cells and at &gt; or = 30% P-gp-positive mononuclear peripheral blood cells </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 42 <z:mp ids='MP_0005481'>CML</z:mp> patients in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase had <z:mpath ids='MPATH_458'>normal</z:mpath> P-gp expression </plain></SENT>
<SENT sid="4" pm="."><plain>P-gp overexpression was demonstrated in four of six patients in accelerated myelogenous blast cell phase and in four of 12 <z:mp ids='MP_0005481'>CML</z:mp>-BC patients </plain></SENT>
<SENT sid="5" pm="."><plain>Of eight <z:mp ids='MP_0005481'>CML</z:mp> patients in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (BC) with <z:mpath ids='MPATH_458'>normal</z:mpath> P-gp expression, partial remission was achieved in three and minor response in five after <z:chebi fb="0" ids="8382">prednisone</z:chebi>/<z:chebi fb="0" ids="36373">vindesine</z:chebi> therapy </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> four of the 12 <z:mp ids='MP_0005481'>CML</z:mp>-BC patients with P-gp overexpression did not respond to this therapy </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> P-gp expression was seen in 41 (85.4%) of 48 untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>While P-gp overexpression did not develop during therapy in any of the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients treated with low-dose ara-C alone, four of eight treated with low-dose ara-C plus GM-CSF and four of 11 treated with low-dose ara-C and IL-3 developed P-gp overexpression after therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, 11 AML patients at primary diagnosis, including five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients with P-gp overexpression, who were treated with <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, <z:chebi fb="0" ids="4911">vepesid</z:chebi>, and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> V (ara-C) showed a complete remission </plain></SENT>
<SENT sid="10" pm="."><plain>Additionally, one <z:chebi fb="0" ids="41977">daunorubicin</z:chebi>-<z:chebi fb="0" ids="28680">cytarabine</z:chebi>-pretreated refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patient was treated with the oral form of the P-gp modulator drug dexniguldipine and achieved complete remission for a duration of 7 months </plain></SENT>
<SENT sid="11" pm="."><plain>Our results suggest that in <z:mp ids='MP_0005481'>CML</z:mp> patients in BC, P-gp expression influences outcome after therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Further more, studies in a larger series of patients are necessary to prove the efficacy and toxicity of <z:chebi fb="0" ids="42068">idarubicin</z:chebi>/<z:chebi fb="0" ids="4911">vepesid</z:chebi> and cytardbine--or dexniguldipine-containing--therapy in relation to P-gp expression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
</text></document>